{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:40:04Z","timestamp":1750707604805,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01430-w","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:17:17Z","timestamp":1750663037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on paraproteinemic neuropathy"],"prefix":"10.1007","volume":"25","author":[{"given":"Rebecca","family":"Traub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"crossref","unstructured":"Min YG, Visentin A, Briani C, Rajabally YA. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management. J Neurol Neurosurg Psychiatry. BMJ Publishing Group; 2024.","DOI":"10.1136\/jnnp-2024-334678"},{"key":"1430_CR2","doi-asserted-by":"crossref","unstructured":"Magy L, Kabor\u00e9 R, Mathis S, Lebeau P, Ghorab K, Caudie C et al. Heterogeneity of polyneuropathy associated with Anti-MAG antibodies. J Immunol Res. 2015;2015.","DOI":"10.1155\/2015\/450391"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","volume":"89","author":"J Svahn","year":"2018","unstructured":"Svahn J, Petiot P, Antoine JC, Vial C, Delmont E, Viala K, et al. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89:499\u2013505.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1430_CR4","doi-asserted-by":"publisher","first-page":"e210000","DOI":"10.1212\/WNL.0000000000210000","volume":"103","author":"CJ Klein","year":"2024","unstructured":"Klein CJ, Triplett JD, Murray DL, Gorsh AP, Shelly S, Dubey D, et al. Optimizing Anti-Myelin-Associated glycoprotein and IgM-Gammopathy testing for neuropathy treatment evaluation. Neurology. 2024;103:e210000.","journal-title":"Neurology"},{"key":"1430_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jns.12156","volume":"21","author":"RI Ferfoglia","year":"2016","unstructured":"Ferfoglia RI, Guimar\u00e3es-Costa R, Viala K, Musset L, Neil J, Marin B, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripheral Nerv Syst. 2016;21:10\u20134.","journal-title":"J Peripheral Nerv Syst"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"J-M L\u00e9ger","year":"2013","unstructured":"L\u00e9ger J-M, Viala K, Nicolas G, Cr\u00e9ange A, Vallat J-M, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80:2217\u201325.","journal-title":"Neurology"},{"key":"1430_CR7","doi-asserted-by":"crossref","unstructured":"Steck AJ. Anti-MAG neuropathy: From biology to clinical management. J Neuroimmunol. Elsevier B.V.; 2021.","DOI":"10.1016\/j.jneuroim.2021.577725"},{"key":"1430_CR8","doi-asserted-by":"publisher","first-page":"116777","DOI":"10.1016\/j.jns.2020.116777","volume":"413","author":"F Massa","year":"2020","unstructured":"Massa F, Zuppa A, Pesce G, Demichelis C, Bergamaschi M, Garnero M, et al. Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. J Neurol Sci. 2020;413:116777.","journal-title":"J Neurol Sci"},{"key":"1430_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1430_CR10","doi-asserted-by":"crossref","unstructured":"Lunn MPT, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane database of systematic reviews. John Wiley and Sons Ltd; 2016.","DOI":"10.1002\/14651858.CD002827.pub4"},{"key":"1430_CR11","doi-asserted-by":"crossref","unstructured":"Castellani F, Visentin A, Campagnolo M, Salvalaggio A, Cacciavillani M, Candiotto C, The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurology(R), neuroimmunology et al. & neuroinflammation. 2020;7.","DOI":"10.1212\/NXI.0000000000000720"},{"key":"1430_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/bloodadvances.2024014115","volume":"9","author":"BM Heyman","year":"2025","unstructured":"Heyman BM, Opat SS, Wahlin BE, Dimopoulos MAC, Castillo JJ, Tedeschi A, et al. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr\u00f6m macroglobulinemia. Blood Adv. 2025;9:722\u20138.","journal-title":"Blood Adv"},{"key":"1430_CR13","doi-asserted-by":"crossref","unstructured":"Castellani F, Visentin A, Schirinzi E, Salvalaggio A, Cacciavillani M, Candiotto C et al. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets. Neurology(R) neuroimmunology & neuroinflammation. 2023;10.","DOI":"10.1212\/NXI.0000000000200122"},{"key":"1430_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","volume":"19","author":"LA Querol","year":"2022","unstructured":"Querol LA, Hartung H-P, Lewis RA, van Doorn PA, Hammond TR, Atassi N, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-Targeted therapies. Neurotherapeutics. 2022;19:864\u201373.","journal-title":"Neurotherapeutics"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJM199003083221002","volume":"322","author":"S Monaco","year":"1990","unstructured":"Monaco S, Bonetti B, Ferrari S, Moretto G, Nardelli E, Tedesco F, et al. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990;322:649\u201352.","journal-title":"N Engl J Med"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1007\/s00415-022-10993-4","volume":"269","author":"K Amaador","year":"2022","unstructured":"Amaador K, Wieske L, Koel-Simmelink MJA, Kamp A, Jongerius I, de Heer K, et al. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol. 2022;269:3700\u20135.","journal-title":"J Neurol"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"e200339","DOI":"10.1212\/NXI.0000000000200339","volume":"12","author":"JPM van de Mortel","year":"2025","unstructured":"van de Mortel JPM, Budding K, Dijkxhoorn K, Minnema MC, Vrancken AFJE, Notermans NC, et al. The role of complement activation in IgM M-Protein-Associated neuropathies. Neurology(R) Neuroimmunol Neuroinflammation. 2025;12:e200339.","journal-title":"Neurology(R) Neuroimmunol Neuroinflammation"},{"key":"1430_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/jns.12547","volume":"28","author":"T Hamadeh","year":"2023","unstructured":"Hamadeh T, van Doormaal PTC, Pruppers MHJ, van de Mortel JPM, Hoeijmakers JGJ, Cornblath DR, et al. IgM anti-MAG\u2009\u00b1\u2009peripheral neuropathy (IMAGiNe) study protocol: an international, observational, prospective registry of patients with IgM M-protein peripheral neuropathies. J Peripheral Nerv Syst. 2023;28:269\u201375.","journal-title":"J Peripheral Nerv Syst"},{"key":"1430_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"IN Van Schaik","year":"2010","unstructured":"Van Schaik IN, L\u00e9ger JM, Nobile-Orazio E, Cornblath DR, Hadden RDM, Koski CL, et al. European federation of neurological societies\/peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society - First revision. J Peripheral Nerv Syst. 2010;15:295\u2013301.","journal-title":"J Peripheral Nerv Syst"},{"key":"1430_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2016-315480","volume":"89","author":"J Fehmi","year":"2018","unstructured":"Fehmi J, Scherer SS, Willison HJ, Rinaldi S. Nodes, Paranodes and neuropathies. J Neurol Neurosurg Psychiatry. 2018;89:61\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1430_CR21","doi-asserted-by":"crossref","unstructured":"Vlam L, Cats EA, Harschnitz O, Jansen MD, Piepers S, Veldink JH, Complement activity is associated with disease severity in multifocal motor neuropathy. Neurology(R), neuroimmunology et al. & neuroinflammation. 2015;2:e119.","DOI":"10.1212\/NXI.0000000000000119"},{"key":"1430_CR22","doi-asserted-by":"crossref","unstructured":"Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H et al. Multifocal motor neuropathy in japan: A nationwide survey on prevalence, clinical profiles, and treatment. Muscle Nerve. 2024.","DOI":"10.1002\/mus.28251"},{"key":"1430_CR23","doi-asserted-by":"crossref","unstructured":"Rajabally YA, Englezou C, Cluett G, Bellanti R, Rinaldi S, Chin MW et al. Diagnosis and management of multifocal motor neuropathy in the united kingdom: A multicentre survey. J Peripheral Nerv Syst. 2025;30.","DOI":"10.1111\/jns.70018"},{"key":"1430_CR24","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1182\/blood.2020007092","volume":"136","author":"M Le Cann","year":"2020","unstructured":"Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood. 2020;136:2428\u201336.","journal-title":"Blood"},{"key":"1430_CR25","doi-asserted-by":"publisher","first-page":"120279","DOI":"10.1016\/j.jns.2022.120279","volume":"438","author":"J-M Vallat","year":"2022","unstructured":"Vallat J-M, Deschamps N, Taithe F, Richard L, Duchesne M, Magy L, et al. Are miller fisher syndrome and CANDA due to a paranodopathy? J Neurol Sci. 2022;438:120279.","journal-title":"J Neurol Sci"},{"key":"1430_CR26","doi-asserted-by":"crossref","unstructured":"Aguirre AS, Vivanco RA, Ortiz JF, Rozen V, InsuastI WE, Fiallos J et al. Efficacy of Rituximab in CANOMAD: A Systematic Review. Cureus. 2023.","DOI":"10.7759\/cureus.39237"},{"key":"1430_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic Immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.","journal-title":"Nat Rev Dis Primers"},{"key":"1430_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133:215\u201323.","journal-title":"Blood"},{"key":"1430_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1468-1331.2010.03215.x","volume":"18","author":"M Matsuda","year":"2011","unstructured":"Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol. 2011;18:604\u201310.","journal-title":"Eur J Neurol"},{"key":"1430_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jns.12428","volume":"26","author":"M Ballegaard","year":"2021","unstructured":"Ballegaard M, Nelson LM, Gimsing P. Comparing neuropathy in multiple myeloma and AL amyloidosis. J Peripher Nerv Syst. 2021;26:75\u201382.","journal-title":"J Peripher Nerv Syst"},{"key":"1430_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13506129.2020.1713081","volume":"27","author":"P Kokotis","year":"2020","unstructured":"Kokotis P, Manios E, Schmelz M, Fotiou D, Dialoupi I, Gavriatopoulou M, et al. Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. Amyloid. 2020;27:103\u201310.","journal-title":"Amyloid"},{"key":"1430_CR32","doi-asserted-by":"crossref","unstructured":"Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc. 2020;95:1852\u201364.","DOI":"10.1016\/j.mayocp.2020.06.029"},{"key":"1430_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based treatment for Immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"},{"key":"1430_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","volume":"95","author":"MA Gertz","year":"2020","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95:848\u201360.","journal-title":"Am J Hematol"},{"key":"1430_CR35","unstructured":"Mauermann ML. Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias."},{"key":"1430_CR36","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","volume":"40","author":"ML Mauermann","year":"2023","unstructured":"Mauermann ML, Clarke JO, Litchy WJ, Obici L, Lousada I, Gertz MA, et al. Peripheral nervous, hepatic, and Gastrointestinal endpoints for AL amyloidosis clinical trials: report from the amyloidosis forum Multi-organ system working group. Adv Ther. 2023;40:4695\u2013710.","journal-title":"Adv Ther"},{"key":"1430_CR37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ajh.26240","volume":"96","author":"A Dispenzieri","year":"2021","unstructured":"Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96:872\u201388.","journal-title":"Am J Hematol"},{"key":"1430_CR38","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1430_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","volume":"120","author":"A D\u2019Souza","year":"2012","unstructured":"D\u2019Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012;120:56\u201362.","journal-title":"Blood"},{"key":"1430_CR40","doi-asserted-by":"publisher","first-page":"E189","DOI":"10.1002\/ajh.26517","volume":"97","author":"HW Tiew","year":"2022","unstructured":"Tiew HW, Sampath VS, Gallardo CA, Christopher D, Chan SSW, Wong SW, et al. Single-agent daratumumab for refractory POEMS syndrome. Am J Hematol. 2022;97:E189\u201391.","journal-title":"Am J Hematol"},{"key":"1430_CR41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.14966","volume":"179","author":"A Nozza","year":"2017","unstructured":"Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017;179:748\u201355.","journal-title":"Br J Haematol"},{"key":"1430_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task Force\u2014Second revision. J Peripheral Nerv Syst. 2021;26:242\u201368.","journal-title":"J Peripheral Nerv Syst"},{"key":"1430_CR43","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/art.34322","volume":"64","author":"MC Sneller","year":"2012","unstructured":"Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835\u201342.","journal-title":"Arthritis Rheum"},{"key":"1430_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"S De Vita","year":"2012","unstructured":"De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843\u201353.","journal-title":"Arthritis Rheum"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01430-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01430-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01430-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:02:33Z","timestamp":1750705353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01430-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01430-w","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"16 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rebecca Traub has received research funding and consulting fees from Argenx, research funding from Immunovant and consulting fees from Takeda. Samuel Rubinstein has received consulting fees from Johnson&Johnson, Brisol-Myers Squibb, and Sanofi. Christopher Dittus has received research funding from Segan, Genentech, and Astrazeneca and consulting fees from Beigene, Genmab, and ADC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"43"}}